CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...
Phase 2
Tigard, Oregon, United States and 21 other locations
immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple...
Phase 2
Portland, Oregon, United States
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Portland, Oregon, United States and 216 other locations
or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib...
Phase 2
Portland, Oregon, United States
or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...
Phase 3
Portland, Oregon, United States and 131 other locations
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC)-...
Phase 1
Portland, Oregon, United States
(weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients....
Phase 1, Phase 2
Portland, Oregon, United States and 1 other location
This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is bei...
Phase 2
Portland, Oregon, United States and 3 other locations
Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") re ...
Phase 2
Portland, Oregon, United States and 3 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Portland, Oregon, United States and 506 other locations
Clinical trials
Research sites
Resources
Legal